Pure Global
NCT05614895

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

A Multicenter, Single-Dose, Uncontrolled, Open-label, One Group Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Patients With Bacterial Infections
Hoffmann-La Roche·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bacterial Infections
Drug/Device/Intervention
RO7223280
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hoffmann-La Roche
Location
Sarasota,Louisville,Royal Oak,Greenville,Portland,Lille,Limoges,Paris,Paris,Strasbourg,Jerusalem,Ramat-Gan,Tel Aviv,Seoul,Seoul,Chisinau, France,Israel,Moldova - Republic of,South Korea,United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Dec 03, 2022
End date
Dec 26, 2023
Enrollment
27 participants
Primary outcome

Plasma Concentrations of RO7223280

Summary

The main aim of the study is to investigate the plasma pharmacokinetics (PK) and safety of
 intravenous (IV) administration of a single dose of 600 mg RO7223280 in critically ill
 participants with bacterial infections.

ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsOther bacterial intestinal infectionsOther bacterial diseasesOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05614895
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05614895 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Bacterial Infections. Target enrollment is 27 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.